GKOS
Glaukos Corporation

861
Loading...
Loading...
News
all
press releases
Glaukos Builds Dual Growth Engines Amid Market Headwinds
GKOS raises revenue guidance after record 1H sales, fueled by iDose TR adoption and expanding international glaucoma momentum.
Zacks·5d ago
News Placeholder
More News
News Placeholder
GKOS Stock Falls Despite Q2 Earnings & Revenues Beat, Guidance Raised
Glaukos' second-quarter results showcase a strong uptick in revenues. However, continued operating loss remains a cause of concern.
Zacks·1mo ago
News Placeholder
Glaukos (GKOS) Reports Q2 Loss, Tops Revenue Estimates
Glaukos (GKOS) delivered earnings and revenue surprises of +7.69% and +8.06%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·1mo ago
News Placeholder
Glaukos Ramps Up iDose TR, Battles Legacy and Reimbursement Risks
GKOS posts record Q1 on iDose TR strength, but reimbursement hurdles and legacy declines may hurt its near-term outlook.
Zacks·2mo ago
News Placeholder
What Makes Glaukos (GKOS) a New Buy Stock
Zacks·3mo ago
News Placeholder
Can Glaukos (GKOS) Climb 34.4% to Reach the Level Wall Street Analysts Expect?
Zacks·3mo ago
News Placeholder
Here's Why You Should Retain Glaukos Stock in Your Portfolio
Zacks·4mo ago
News Placeholder
Glaukos Announces FDA Acceptance of NDA Submission for Epioxa
Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today...
Business Wire·7mo ago
News Placeholder
Glaukos Announces Fourth Quarter and Full Year 2024 Financial Results
Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today...
Business Wire·7mo ago
News Placeholder
Glaukos to Release Fourth Quarter and Full Year 2024 Financial Results after Market Close on February 20
Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans...
Business Wire·8mo ago

Latest GKOS News

View

Advertisement. Remove ads.

Advertisement. Remove ads.

Advertisement. Remove ads.